CFTR corrector therapy attenuates HF-associated systemic and lung-specific S1P augmentation and results in lower S1P1 positivity of several splenic immune cell subsets, suggesting an important role for the CFTR-S1P axis in HF-mediated pulmonary inflammation. This evidence concerns the gene MBTPS1 and hydrops fetalis.